Skip to main content

Lilly Ostrovsky

Medical Writer
Authored Items
Eylea (Aflibercept), a VEGF Receptor Inhibitor, Receives New Indication for All Stages of Diabetic Retinopathy
Lilly Ostrovsky
2019 Payers' Guide Mid-Year Addendum in FDA Approvals
Imbruvica (Ibrutinib) plus Gazyva (Obinutuzumab) First Chemotherapy-Free Combination Approved as First-Line Treatment for Patients with CLL or SLL
Lilly Ostrovsky
2019 Payers' Guide Mid-Year Addendum in FDA Approvals
Mavenclad (Cladribine) First Short-Course Oral Therapy Approved for Relapsing-Remitting Multiple Sclerosis and Active Secondary Progressive Disease
Lilly Ostrovsky
2019 Payers' Guide Mid-Year Addendum in FDA Approvals
Payers’ Perspective: Incorporating Real-World Evidence in Patient Care
Lilly Ostrovsky
April 2017 Vol 10, No 2 in Conference Correspondent, Conference Highlights AMCP
Implications of Real-World Data and Pharmacoeconomics for Managed Care
Lilly Ostrovsky
May 2016 Vol 9, No 3 in Conference Highlights AMCP
New Data Show Osimertinib Effective as First-Line Treatment of NSCLC with EGFR Mutation
Lilly Ostrovsky
Web Exclusives in In the News, Lung Cancer, Oncology
Atezolizumab First PD-L1 Inhibitor Approved by the FDA for Advanced or Metastatic Urothelial Cancer
Lilly Ostrovsky
Web Exclusives in FDA Approvals
Last modified: August 13, 2019